Reviewed B2B product content
An audience-specific communication plan connects the selected business need with approved information and a useful next action.
Pharma & medtech / Reviewed communication
Clear information. Responsible review.
Choose the channels, content and enquiry journey around the business problem—not a fixed number of posts.
What the work can include
Reviewed communication deliverables for pharma & medtech
Intended-use information design
Existing page structure, copy and calls to action are reviewed together. New pages, integrations and custom software are scoped separately.
Trade and distributor enquiry journeys
Channels are selected only after checking scope, audience relevance, permitted use and the readiness of the next step. Spend is approved separately.
Approved event and exhibition materials
The form or handoff asks for only the information needed for a useful response. A named client owner receives the next action.
Document-request handoffs
Workflow setup includes agreed triggers, permissions, exception handling and staff instructions. Usage charges are not part of the service fee.
Audience-appropriate discoverability planning
A reporting definition distinguishes activity, valid enquiries and client-recorded outcomes. Unavailable attribution is not invented.
Product, medical, regulatory and legal review is required before publication. This is not a direct-to-consumer prescription-promotion package. No unsupported efficacy or safety claims.
Built for pharma & medtech
Know the rules.
Show the proof.
Industry expertise is the part a generic agency or an AI tool cannot fake. Every claim we help publish is checked against these first.
Rules we work within
- Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
- Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024
- Drugs and Cosmetics Rules on promoting prescription medicines to the public
- ASCI guidelines on health claims
Pointers for review, not legal advice. Specialist sign-off is arranged where your claims need it.
What a trustworthy pharma & medtech brand shows
- Approved, referenced product information
- Clear manufacturing and quality credentials
- Pharmacovigilance / adverse-event contact
- Separate HCP information
Use this to judge any provider—including us.
What reaches your team
A useful handover.
Not a mystery report.
- The approved work plan and final deliverable folder
- Access and ownership record for agreed accounts
- Approval log and factual sources provided by your team
- Measurement definitions and the limits of available data
- Priority recommendations for the next phase
Free · 2 minutes · no email
How healthy is your
pharma & medtech brand?
Answer eight quick questions written for pharma & medtech businesses. Get a score, your weakest area and the first three things to fix.
- Sample questionEvery product claim links to an approved source and a named reviewer.
- Sample questionHealthcare professionals and the public reach different, appropriate information.
- Sample questionCorporate, product and therapy-area brands follow one clear hierarchy.
The customer experience
Evidence-to-information system.
These are the stages we design around. Open the interactive map to inspect the work and handoff.
- 01
Define
Confirm audience, intended use and permitted communication scope.
Approved communication brief - 02
Evidence
Map claims to current approved supporting information.
Evidence and version register - 03
Explain
Design clear materials for the approved audience.
Reviewed product or capability material - 04
Connect
Route appropriate business enquiries to the relevant team.
B2B enquiry and document handoff
Reviewed communication questions
Reviewed communication:
common questions.
Still unsure? Ask us directly.
What is included in reviewed communication for pharma & medtech?
Typical deliverables are reviewed b2b product content, intended-use information design, trade and distributor enquiry journeys, approved event and exhibition materials. The exact quantities, revisions and handover are fixed in the statement of work before work begins.
How much does reviewed communication cost?
Work usually starts with Diagnose the problem (from ₹40,000), which confirms whether reviewed communication is the real priority. The closest engagement, Fix my claim-approval workflow, has a proposed starting fee of ₹65,000 one-time. A final quotation follows the scope agreement.
How do you measure reviewed communication?
Against measures agreed up front, such as approved material coverage, review-cycle turnaround, qualified b2b enquiries. Activity, valid enquiries and client-recorded outcomes are reported separately, and missing attribution is documented rather than estimated.
What do you need from us?
A named reviewer, accurate business information, authorised images and evidence, access to the relevant accounts and an operational contact who owns the next customer action.
Can pharma companies advertise medicines on their website?
Prescription medicines should not be promoted to the public, and certain disease claims are prohibited outright. Corporate information, capabilities and approved product information for professionals are possible with medical and regulatory review.
What is UCPMP 2024?
The Uniform Code for Pharmaceutical Marketing Practices sets expectations for how pharmaceutical companies promote products and engage healthcare professionals, including evidence-based claims and restrictions on gifts and hospitality.
The next considered step
Evidence before expression.
Let’s start there.
Tell us about the business, the gap and the work you need. Start with a useful brief—not a bigger package.